AYTU Stock Analysis: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$2.13
-0.02 (-0.93%)
▼
5d:
-6.17%
30d:
-17.12%
90d:
-7.39%
HOLD
LOW Confidence
Analysis Updated: May 21, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AYTU shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AYTU shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $2.13, which is considered oversold relative to its 30-day fair value range of $2.28 to $2.62. From a valuation perspective, the stock is trading at a discount (Forward PE: -42.6) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a downtrend. Immediate support is located at $1.98, while resistance sits at $2.55.
Market Sentiment: AYTU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.33 (+338.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AYTU is in a downtrend. Immediate support is located at $1.98, while resistance sits at $2.55.
Market Sentiment: AYTU has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.33 (+338.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.28 -
$2.62
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 338.2% below Wall St target ($9.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -6.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.28 -
$2.62
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.98
Resistance Level
$2.55
Current Trend
Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-42.60
Wall Street Target
$9.33
(+338.2%)
Revenue Growth (YoY)
-32.7%
Profit Margin
-60.2%
PE vs Historical
-42.6 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: May 21, 2026 10:08 PM ET
Data refreshes hourly during market hours. Next update: 11:08 PM
Data refreshes hourly during market hours. Next update: 11:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 57 HOLD |
